Last week, the UK Supreme Court held a four-day hearing on an issue that should help to determine the level of evidence pharmaceutical companies will have to provide to demonstrate the “plausibility” of a patent claim, particularly one that applies to second medical use patents.
As well hopefully elucidating the evidence required for plausibility, the ruling on this case, which involves Pfizer Inc.’s Lyrica...





